Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth von Guggenberg

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Current Medicinal Chemistry|June 27, 2020
Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future DirectionsMaximilian Klingler, Anton Amadeus Hörmann, Elisabeth Von Guggenberg
Journal of Pharmaceutical Sciences|September 7, 2004
Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosisElisabeth Von Guggenberg, Renata Mikolajczak, Barbara Janota, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 6, 2005
Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotideElisabeth von Guggenberg, Barbara Penz, Georg Kemmler, et al.
Nuclear Medicine and Biology|August 27, 2023
Automated production of [<sup>68</sup>Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis moduleMartin Kraihammer, Elisabeth von Guggenberg, Anton Amadeus Hörmann, et al.
Cancers|November 27, 2021
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting RadiopharmaceuticalsElisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, et al.
Pharmaceuticals (Basel, Switzerland)|January 18, 2019
Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99mMaximilian Klingler, Christine Rangger, Dominik Summer, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|January 6, 2017
Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugatesNathalie M Grob, Martin Behe, Elisabeth von Guggenberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotidesElisabeth von Guggenberg, Soraya Shahhosseini, Ingrid Koslowsky, et al.
Pharmaceuticals (Basel, Switzerland)|June 16, 2019
Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. <i>Pharmaceuticals</i> 2019, <i>12</i>, 13Maximilian Klingler, Christine Rangger, Dominik Summer, et al.
Nuclear Medicine and Biology|February 15, 2011
Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivativeMeltem Ocak, Anna Helbok, Elisabeth von Guggenberg, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Current Medicinal Chemistry|June 27, 2020
Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future DirectionsMaximilian Klingler, Anton Amadeus Hörmann, Elisabeth Von Guggenberg
Journal of Pharmaceutical Sciences|September 7, 2004
Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosisElisabeth Von Guggenberg, Renata Mikolajczak, Barbara Janota, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 6, 2005
Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotideElisabeth von Guggenberg, Barbara Penz, Georg Kemmler, et al.
Nuclear Medicine and Biology|August 27, 2023
Automated production of [<sup>68</sup>Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis moduleMartin Kraihammer, Elisabeth von Guggenberg, Anton Amadeus Hörmann, et al.
Cancers|November 27, 2021
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting RadiopharmaceuticalsElisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, et al.
Pharmaceuticals (Basel, Switzerland)|January 18, 2019
Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99mMaximilian Klingler, Christine Rangger, Dominik Summer, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|January 6, 2017
Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugatesNathalie M Grob, Martin Behe, Elisabeth von Guggenberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotidesElisabeth von Guggenberg, Soraya Shahhosseini, Ingrid Koslowsky, et al.
Pharmaceuticals (Basel, Switzerland)|June 16, 2019
Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. <i>Pharmaceuticals</i> 2019, <i>12</i>, 13Maximilian Klingler, Christine Rangger, Dominik Summer, et al.
Nuclear Medicine and Biology|February 15, 2011
Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivativeMeltem Ocak, Anna Helbok, Elisabeth von Guggenberg, et al.
Pageof 7